KR20110137307A - 치료를 모니터링하기 위해 바이오마커를 사용하는 방법 또는 시스템 - Google Patents

치료를 모니터링하기 위해 바이오마커를 사용하는 방법 또는 시스템 Download PDF

Info

Publication number
KR20110137307A
KR20110137307A KR1020117021089A KR20117021089A KR20110137307A KR 20110137307 A KR20110137307 A KR 20110137307A KR 1020117021089 A KR1020117021089 A KR 1020117021089A KR 20117021089 A KR20117021089 A KR 20117021089A KR 20110137307 A KR20110137307 A KR 20110137307A
Authority
KR
South Korea
Prior art keywords
cells
monitoring
treatment
biomarker
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020117021089A
Other languages
English (en)
Korean (ko)
Inventor
도쿠조 아라오
가나에 구도
가즈히코 나카가와
가즈토 니시오
Original Assignee
베링거 인겔하임 인터내셔날 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42129920&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20110137307(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 베링거 인겔하임 인터내셔날 게엠베하 filed Critical 베링거 인겔하임 인터내셔날 게엠베하
Publication of KR20110137307A publication Critical patent/KR20110137307A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5064—Endothelial cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Indole Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020117021089A 2009-03-12 2010-03-11 치료를 모니터링하기 위해 바이오마커를 사용하는 방법 또는 시스템 Withdrawn KR20110137307A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09154964 2009-03-12
EP09154964.2 2009-03-12

Publications (1)

Publication Number Publication Date
KR20110137307A true KR20110137307A (ko) 2011-12-22

Family

ID=42129920

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117021089A Withdrawn KR20110137307A (ko) 2009-03-12 2010-03-11 치료를 모니터링하기 위해 바이오마커를 사용하는 방법 또는 시스템

Country Status (24)

Country Link
US (1) US8802384B2 (https=)
EP (1) EP2406628A1 (https=)
JP (1) JP5667581B2 (https=)
KR (1) KR20110137307A (https=)
CN (1) CN102334030A (https=)
AR (1) AR076113A1 (https=)
AU (1) AU2010223256B2 (https=)
BR (1) BRPI1011688A2 (https=)
CA (1) CA2755055A1 (https=)
CL (1) CL2011002260A1 (https=)
CO (1) CO6430497A2 (https=)
EA (1) EA201101300A1 (https=)
EC (1) ECSP11011323A (https=)
IL (1) IL214747A0 (https=)
MA (1) MA33120B1 (https=)
MX (1) MX2011009482A (https=)
NZ (1) NZ594843A (https=)
PE (1) PE20120592A1 (https=)
SG (1) SG174324A1 (https=)
TN (1) TN2011000457A1 (https=)
TW (1) TW201100802A (https=)
UA (1) UA107789C2 (https=)
UY (1) UY32482A (https=)
WO (1) WO2010103058A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA107560C2 (uk) * 2008-06-06 2015-01-26 Фармацевтична лікарська форма для негайного вивільнення похідної індолінону
MX2010013203A (es) * 2008-06-06 2011-02-25 Boehringer Ingelheim Int Forma de dosificacion farmaceutica en capsula que comprende una formulacion en suspension de un derivado de indolinona.
US20170065529A1 (en) 2015-09-09 2017-03-09 Boehringer Ingelheim International Gmbh Pharmaceutical dosage form for immediate release of an indolinone derivative
US20140350022A1 (en) 2013-05-10 2014-11-27 Boehringer Ingelheim International Gmbh Efficacious treatment of NSCLC and predictive clinical marker of the responsiveness of a tumour to a treatment
CN104003925B (zh) * 2013-06-05 2016-03-30 四川大学 吲哚酮化合物或其衍生物及其用途
JP6799201B2 (ja) 2013-07-31 2020-12-16 アヴァリン ファーマ インク． エアロゾルチロシンキナーゼ阻害剤の化合物、及びその使用
US11397178B2 (en) 2016-10-28 2022-07-26 Cedars-Sinai Medical Center Method of predicting progression of idiopathic pulmonary fibrosis and monitoring of therapeutic efficacy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6762180B1 (en) * 1999-10-13 2004-07-13 Boehringer Ingelheim Pharma Kg Substituted indolines which inhibit receptor tyrosine kinases
UA75054C2 (uk) 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу
DE10233500A1 (de) * 2002-07-24 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel
DE10237423A1 (de) 2002-08-16 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen
US20040204458A1 (en) * 2002-08-16 2004-10-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of Lck inhibitors for treatment of immunologic diseases
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
EP1571225A1 (en) 2004-03-02 2005-09-07 PrimaGen Holding B.V. Diagnosis of a disease and monitoring of therapy using the AC133 gene
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
EP1777523A1 (en) 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
US8557531B2 (en) 2006-04-18 2013-10-15 Wellstat Biologics Corporation Detection of circulating endothelial cells
EP1870400A1 (en) 2006-06-08 2007-12-26 Boehringer Ingelheim Pharma GmbH & Co. KG Salts and crystalline salt forms of an 2-indolinone derivative
CA2662591A1 (en) * 2006-09-07 2008-03-13 Astrazenca Ab Method for evaluating patients for treatment with drugs targeting ret receptor tyrosine kinase
KR20090128474A (ko) 2007-04-13 2009-12-15 브리스톨-마이어스 스큅 컴퍼니 혈관 내피 성장인자 수용체-2 조절제에 대한 감수성을 판정하기 위한 방법 및 바이오마커
WO2008134526A2 (en) 2007-04-27 2008-11-06 University Of Florida Research Foundation Inc. Glycoprotein profiling of bladder cancer

Also Published As

Publication number Publication date
US20100233705A1 (en) 2010-09-16
JP5667581B2 (ja) 2015-02-12
EP2406628A1 (en) 2012-01-18
AU2010223256A1 (en) 2011-09-15
CA2755055A1 (en) 2010-09-16
CO6430497A2 (es) 2012-04-30
IL214747A0 (en) 2011-11-30
ECSP11011323A (es) 2011-10-31
EA201101300A1 (ru) 2012-04-30
AR076113A1 (es) 2011-05-18
PE20120592A1 (es) 2012-06-09
UY32482A (es) 2010-10-29
SG174324A1 (en) 2011-10-28
NZ594843A (en) 2014-03-28
CN102334030A (zh) 2012-01-25
TN2011000457A1 (en) 2013-03-27
MA33120B1 (fr) 2012-03-01
AU2010223256B2 (en) 2014-08-21
UA107789C2 (en) 2015-02-25
US8802384B2 (en) 2014-08-12
WO2010103058A1 (en) 2010-09-16
TW201100802A (en) 2011-01-01
CL2011002260A1 (es) 2012-03-23
MX2011009482A (es) 2011-09-27
JP2012520446A (ja) 2012-09-06
BRPI1011688A2 (pt) 2016-03-22

Similar Documents

Publication Publication Date Title
Narayan et al. PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial
JP5795311B2 (ja) 抗体ベースのアレイを使用する胃癌療法のための薬物選択
JP5352585B2 (ja) 抗体アレイを用いた肺癌治療のための薬剤選択
Mathivet et al. Dynamic stroma reorganization drives blood vessel dysmorphia during glioma growth
Dobersalske et al. Cranioencephalic functional lymphoid units in glioblastoma
US8802384B2 (en) Method or system using biomarkers for the monitoring of a treatment
JP2022513685A (ja) 養子細胞療法を用いた処置のための方法
MX2010009140A (es) Seleccion de farmacos para terapia de cancer de mama utilizando matrices basadas en anticuerpos.
US20100203043A1 (en) Treatment and diagnosis of metastatic prostate cancer with inhibitors of epidermal growth factor receptor (egfr)
Fan et al. Interleukin‐1β augments the angiogenesis of endothelial progenitor cells in an NF‐κB/CXCR7‐dependent manner
Gotesman et al. mTOR inhibition enhances efficacy of dasatinib in ABL-rearranged Ph-like B-ALL
Chen et al. Tumor-derived exosomal ICAM1 promotes bone metastasis of triple-negative breast cancer by inducing CD8+ T cell exhaustion
WO2021075528A1 (ja) 薬物毒性評価方法
CN111971557A (zh) 嗜中性粒细胞亚型
Han et al. CXCR4-targeted PET imaging in rheumatoid arthritis: a novel approach for monitoring disease activity and therapeutic response
JP7255896B2 (ja) シクロホスファミド療法に対する応答者の予測
Comin-Anduix et al. Modulation of cell signaling networks after CTLA4 blockade in patients with metastatic melanoma
HK1162668A (en) Method or system using biomarkers for the monitoring of a treatment
Hsu et al. Secreted frizzled-related protein 2 monoclonal antibody-mediated IFN-ϒ reprograms tumor-associated macrophages to suppress triple negative breast cancer
Bahadur et al. Preclinical platform using a triple-negative breast cancer syngeneic murine model to evaluate immune checkpoint inhibitors
Márquez Leveraging Protein Evolution to Elucidate Oncogenic Cytokine Signaling Axes and Develop Novel Therapeutics for Highly Lethal Cancers
CN108070554A (zh) 一种用于体外扩增细胞毒性γδT淋巴细胞的药物组合及其扩增方法
Vincze Describing the Clinical and Public Health Utility of a Novel Immuno-PET Imaging Agent, 89Zr-DFO-CD69 Ab
JP2025531809A (ja) オルガノイドを用いて腫瘍反応性免疫集団を増強するシステムおよび方法
TW202603361A (zh) 胰臟癌患者之ｉｌ—６抑制劑與化學療法之併用療法之治療效果預測法

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20110908

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid